Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
E David Crawford, Axel Heidenreich, Nathan Lawrentschuk, Bertrand Tombal, Antonio CL Pompeo, Arturo Mendoza-Valdes, Kurt Miller, Frans MJ Debruyne, Laurence Klotz
Prostate Cancer and Prostatic Diseases | NATURE PUBLISHING GROUP | Published : 2019
BACKGROUND: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies. METHODS: This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in ther..View full abstract
Editorial support was provided by Jocelyn Hybiske, Ph.D., a consultant of Xelay Acumen, Inc., funded by TOLMAR Inc., Fort Collins, CO.